Cosentyx (secukinumab) / Novartis  >>  Phase 3
Welcome,         Profile    Billing    Logout  

37 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cosentyx (secukinumab) / Novartis
NCT02471144 / 2014-005663-32: Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Hourglass Jan 2023 - Dec 2023 : Data from trial for psoriasis
Completed
3
162
Europe, Japan, US, RoW
Experimental : Secukinumab low dose, AIN457 low dose, Experimental: Secukinumab high dose, AIN457 high dose, Placebo Comparator: Secukinumab Placebo, AIN457 placebo, Active Comparator: Etanercept, Etanercept
Novartis Pharmaceuticals
Chronic Severe Plaque-type Psoriasis
12/18
03/23
BE RADIANT, NCT03536884 / 2017-003784-35: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Checkmark Efficacy and safety data from BE RADIANT in moderate to severe plaque psoriasis
Apr 2021 - Apr 2021: Efficacy and safety data from BE RADIANT in moderate to severe plaque psoriasis
Checkmark From BE RADIANT trial for psoriasis at AAD 2021
Feb 2021 - Feb 2021: From BE RADIANT trial for psoriasis at AAD 2021
Checkmark From BE RADIANT trial for psoriasis
More
Completed
3
743
Europe, Canada, US, RoW
Bimekizumab, UCB4940, Secukinumab, COSENTYX®, Placebo, PBO
UCB Biopharma SRL
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
09/19
08/23
NCT03668613 / 2017-004515-39: Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Hourglass Jan 2023 - Dec 2023 : Data from trial for psoriasis
Completed
3
84
Europe, US, RoW
secukinumab low dose, AIN457, secukinumab high dose
Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque-type Psoriasis
09/19
09/23
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms

Not yet recruiting
3
270
Europe
Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung
Universitätsklinikum Erlangen, Universitätsklinikum Erlangen
Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20]
 
 
2019-004246-15: Study to assess efficacy of secukinumab compared to ustekinumab in adult patients with psoriatic arthritis and previous TNFα-inhibitor treatment failure

Not yet recruiting
3
310
Europe
Secukinumab, Ustekinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx, Stelara
Novartis Pharma GmbH, Novartis Pharma GmbH
Psoriatic arthritis, Psoriatic arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2019-003168-37: Study in patients with plaque psoriasis with coexisting non-alcoholic fatty liver disease

Not yet recruiting
3
90
Europe
Secukinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx
Novartis Pharma GmbH, Novartis Pharma GmbH
plaque psoriasis with coexisting non-alcoholic fatty liver disease, plaque psoriasis with coexisting non-alcoholic fatty liver disease, Body processes [G] - Immune system processes [G12]
 
 
2020-004809-31: Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).

Not yet recruiting
3
349
Europe, RoW
Cosentyx, Prednisone, AIN457, Solution for injection in pre-filled syringe, Capsule, hard + tablet, Cosentyx, Prednisone
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Pharma AG
giant cell arteritis, giant cell arteritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2021-001256-34: study to demonstrate the efficacy and safety of secukinumab up to 224 weeks in subjects with active peripheral spondyloarthritis (pSpA). Klinické skúšanie na zhodnotenie účinnosti a bezpečnosti sekukinumabu do 224 týždňov liečby u pacientov s aktívnou periférnou spondyloartritídou (pSpA)

Ongoing
3
324
Europe
Solution for injection in pre-filled syringe, Cosentyx
Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Peripheral Spondyloarthritis, Peripheral Spondyloarthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
NCT04156620: Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Hourglass Jan 2023 - Dec 2023 : Final data from INVIGORATE-1 trial for axial spondyloarthritis
Hourglass Jan 2022 - Dec 2022 : Primary data from INVIGORATE-1 trial for axial spondyloarthritis
Completed
3
527
Europe, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Ankylosing Spondylitis
02/22
12/22
NCT04711902: Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

Completed
3
41
RoW
AIN457, Secukinumab, Secukinumab Placebo
Novartis Pharmaceuticals
Psoriatic Arthritis
06/22
03/23
2021-002622-24: Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission

Not yet recruiting
3
146
Europe
Secukinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx
Novartis Pharma GmbH, Novartis Pharma GmbH
Giant Cell Arteritis, Giant Cell Arteritis, Body processes [G] - Immune system processes [G12]
 
 
2021-005772-19: An extension clinical trial of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis Un estudio de extensión de secukinumab subcutáneo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo en pacientes con nefritis lúpica activa.

Ongoing
3
310
Europe, RoW
Solution for injection in pre-filled syringe, Cosentyx
Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG
Lupus Nephritis Nefritis lúpica, Lupus Nephritis is an inflammation of kidneys caused by systemic lupuserythematosus, an autoimmune disease (body's immune system targetsits own body tissues) that can affect any part of the body. Nefritis lúpica:inflamación de los riñones causada por lupus eritematoso sistémico,enfermedad autoinmune (el sistema inmune ataca a los tejidos propios) que puede afectar a cualquier parte del cuerpo, Diseases [C] - Immune System Diseases [C20]
 
 
2018-003882-32: Study in patients with active axial spondyloarthritis to assess efficacy of a treat-to-target treatment strategy with secukinumab compared to a standard-of-care treatment.

Not yet recruiting
3
300
Europe
Secukinumab, Adalimumab, AIN457, GP2017, Solution for injection in pre-filled syringe, Cosentyx, Hyrimoz
Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma S.A.S
Active axial spondyloarthritis (axSpA), Active axial spondyloarthritis (axSpA), Body processes [G] - Immune system processes [G12]
 
 
2022-001516-26: Study of efficacy and safety and of AIN457/secukinumab in patients with rotator cuff tendinopathy

Not yet recruiting
3
430
Europe
Secukinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx
Novartis Pharma GmbH, Novartis Pharma GmbH
Rotator cuff tendinopathy, Rotator cuff tendinopathy, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2022-001770-59: Comparison of the efficacy and safety between two study drugs in skin disease patients

Not yet recruiting
3
500
Europe
Recombinant human monoclonal IgG1 antibody, Cosentyx 150 mg solution for injection in pre-filled syringe, BAT2306, NA, Solution for injection in pre-filled syringe, Cosentyx®
Bio-Thera Solutions, Ltd., Bio-Thera Solutions, Ltd.
Moderate to Severe Plaque Psoriasis, It is an autoimmune diseas characterized by raised areas of abnormal skin. These areas are red, or purple on some people with darker skin, dry, itchy, and scaly., Diseases [C] - Immune System Diseases [C20]
 
 
2019-001177-90: Study to demonstrate the efficacy, safety and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in subjects with active axSpA

Not yet recruiting
3
500
Europe, RoW
Secukinumab, AIN457, Concentrate for solution for infusion
Novartis Pharma AG, Novartis Pharma AG
Axial Spondyloarthritis, Axial Spondyloarthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2020-001611-24: Study of efficacy and safety of secukinumab in adult patients with active, moderate to severe thyroid eye disease

Not yet recruiting
3
70
Europe
Secukinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx
Novartis Pharma GmbH, Novartis Pharma GmbH
Active, moderate to severe thyroid eye disease, Thyroid eye disease, Diseases [C] - Eye Diseases [C11]
 
 
ORBIT, NCT04737330: A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)

Terminated
3
28
Europe
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Thyroid Eye Disease, Graves Orbitopathy
05/23
05/23
NCT05232864 / 2021-005772-19: Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

Terminated
3
31
Europe, Japan, RoW
Secukinumab, AIN457
Novartis Pharmaceuticals, Novartis Pharma AG
Lupus Nephritis
08/23
08/23
SELUNE, NCT04181762 / 2019-003211-57: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Terminated
3
275
Europe, Canada, Japan, US, RoW
secukinumab, AIN457
Novartis Pharmaceuticals
Lupus Nephritis
09/23
09/23
AgAIN, NCT04632927: Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

Active, not recruiting
3
119
Europe
Secukinumab, AIN457, Ustekinumab
Novartis Pharmaceuticals
Psoriatic Arthritis
10/24
10/24
NCT04179175 / 2019-003230-17: Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

Active, not recruiting
3
701
Europe, Canada, Japan, US, RoW
secukinumab, AIN457
Novartis Pharmaceuticals
Hidradenitis Suppurativa
05/23
07/26
REPLENISH-EXT, NCT06331312: Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

Recruiting
3
300
Europe, Japan, US, RoW
Secukinumab
Novartis Pharmaceuticals
Polymyalgia Rheumatica
06/28
07/28
NCT05377944: Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

Active, not recruiting
3
502
RoW
BAT2306, Recombinant human monoclonal antibody against IL-17A, EU-approved Cosentyx, secukinumab injection
Bio-Thera Solutions
Plaque Psoriasis
07/24
12/24
NCT06398652: Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis

Recruiting
3
336
RoW
CMAB015, Secukinumab, Cosentyx
Taizhou Mabtech Pharmaceutical Co.,Ltd
Psoriasis
05/25
12/25
NCT04732117: Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis

Active, not recruiting
3
138
RoW
Secukinumab, AIN457, Placebo, AIN457 Placebo
Novartis Pharmaceuticals
Non-radiographic Axial Spondyloarthritis
04/24
02/25
NCT03769168 / 2018-002521-30: An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Calendar Jan 2025 - Dec 2025: Data from trial for psoriatic arthritis
Active, not recruiting
3
55
Europe, US, RoW
AIN457, Secukinumab
Novartis Pharmaceuticals
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
10/24
11/24
NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Recruiting
3
270
Europe
Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara
University of Erlangen-Nürnberg Medical School
Psoriatic Arthritis, Withdrawal, Reduction
10/24
10/25
NCT05722522: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Active, not recruiting
3
34
Europe, Canada, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Active, not recruiting
3
61
Europe, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Active, not recruiting
3
354
Europe, Canada, US, RoW
Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg
Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
04/25
07/27
LZM012-III, NCT06110676: A Study to Evaluate the Efficacy and Safety of LZM012

Recruiting
3
918
RoW
LZM012, Secukinumab
Livzon Pharmaceutical Group Inc.
Psoriasis
04/25
06/25
UnchAIN, NCT05569174: Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy

Active, not recruiting
3
62
Europe
secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Tendinopathy
12/24
12/24
IL-17 inhibitors in GPP, ChiCTR2400083906: Evaluation of IL-17 inhibitors in generalized pustular psoriasis

Not yet recruiting
3
20
 
Secukinumab 300mg subcutaneous injection at weeks 0, 1, 2, 3, 4, 8, 12, 16
The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University, Bethune Charitable Foundation
generalized pustular psoriasis
 
 
GigAINt, NCT05380453: Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission

Recruiting
3
146
Europe
Secukinumab 300 mg, s.c., Cosentyx, AIN457, Placebo to match Secukinumab, s.c.
Novartis Pharmaceuticals
Giant Cell Arteritis
02/26
07/26
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Active, not recruiting
3
360
Europe, Canada, Japan, US, RoW
Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab
Novartis Pharmaceuticals
Polymyalgia Rheumatica
09/25
02/26
2015-000762-65: Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosu

Ongoing
2/3
7
Europe
Cosentyx, EU/1/14/980/002; EU/1/14/980/003, Solution and suspension for suspension for injection in pre-filled syringe, Cosentyx®
Technische Universität München, School of Medicine, represented by Dean, Novartis Pharmaceuticals AG
Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising., Pyoderma gangrenosum is an autoinflammatory disease. It is difficut to treat. Treatment with a new drug against IL17 seems promising., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 

Download Options